Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $69.24 USD
Change Today 0.00 / 0.00%
Volume 0.0
TEVJF On Other Exchanges
Symbol
Exchange
New York
OTC US
Mexico
Tel Aviv
Frankfurt
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical ind ltd (TEVJF) Snapshot

Open
$68.50
Previous Close
$69.24
Day High
$69.24
Day Low
$68.50
52 Week High
07/27/15 - $69.24
52 Week Low
10/6/14 - $53.00
Market Cap
58.9B
Average Volume 10 Days
45.0
EPS TTM
--
Shares Outstanding
850.0M
EX-Date
08/20/15
P/E TM
--
Dividend
$1.36
Dividend Yield
1.94%
Current Stock Chart for TEVA PHARMACEUTICAL IND LTD (TEVJF)

teva pharmaceutical ind ltd (TEVJF) Details

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Nuvigil and Provigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora/Effentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; Zecuity for the treatment of migraine in adults; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. This segment’s products in the respiratory market include ProAir, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Trisenox, Granix, Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, and Eporatio products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, and Zoely. In addition, the company provides branded over-the-counter medicines in the categories of cough/cold and allergy, digestive wellness, vitamins, minerals and supplements, analgesics, and skin medications; and sells third-party products, such as medical devices and other miscellaneous items. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Petach Tikva, Israel.

43,009 Employees
Last Reported Date: 02/9/15
Founded in 1901

teva pharmaceutical ind ltd (TEVJF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical ind ltd (TEVJF) Key Developments

Teva Pharmaceutical Industries Ltd. Declares Cash Dividend for the Second Quarter of 2015, Payable on September 3, 2015

The Board of Directors of Teva Pharmaceutical Industries Ltd. at its meeting on July 26, 2015, declared a cash dividend for the second quarter of 2015 of $0.34. The record date will be August 20, 2015, and the payment date will be September 3, 2015. Tax will be withheld at a rate of 15%.

European Medicines Agency Confirms Teva Pharmaceutical Industries' Successful Validation of Reslizumab Marketing Authorization Application

Teva Pharmaceutical Industries Limited announced that it has successfully filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for reslizumab. Reslizumab is a humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb) for the treatment of inadequately controlled asthma in adult patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based regimen. The MAA for reslizumab includes data from Teva’s Phase III BREATH clinical trial program. The program consisted of four separate placebo-controlled Phase III trials specifically designed to include a targeted population of 1,700 adult and adolescent asthma patients with elevated blood eosinophils, whose symptoms were inadequately controlled with inhaled corticosteroid-based therapies. Results from these studies demonstrated that reslizumab, compared to placebo, reduced asthma exacerbation rates by at least half (50-60%) and provided significant improvement in lung function, quality of life and other secondary measures of asthma control as add-on therapy. Common adverse events in the reslizumab treatment group were comparable to placebo and included worsening of asthma, nasopharyngitis, upper respiratory infections, sinusitis, influenza and headache. Two anaphylactic reactions were reported and resolved following medical treatment at the study site.

Teva Pharmaceutical Industries Limited Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reports Impairment of Long-Lived Assets for the Second Quarter Ended June 30, 2015; Revised Earnings Guidance for the Year 2015; Provides Earnings Guidance for the Year 2016

Teva Pharmaceutical Industries Limited reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net revenues of $4.966 billion compared to $5.045 billion, down 2% compared to the second quarter of 2014. Excluding the impact of foreign exchange fluctuations and the sale of U.S. OTC plant in July 2014, revenues increased 6% compared to the second quarter of 2014. Operating income was $662 million compared to $925 million a year ago. Income before income taxes was $621 million compared to $847 million a year ago. Net income attributable to the company was $539 million or $0.63 per diluted share compared to $748 million or $0.87 per diluted share a year ago. Non-GAAP net income attributable to the company was $1,230 million compared to $1,069 million a year ago. Non-GAAP diluted earnings per share of $1.43 compared to $1.25, up 15% compared to the second quarter of 2014. Non-GAAP operating income was $1.610 billion compared to $1.387 billion, an increase of 16% compared to the second quarter of 2014. Net cash provided by operating activities was $1,480 million compared to $1,053 million a year ago. Free cash flow was $1.3 billion, up 51% compared to the second quarter of 2014. For the six months, the company reported net revenues of $9,948 million compared to $10,046 million a year ago. Operating income was $1,411 million compared to $1,897 million a year ago. Income before income taxes was $1,178 million compared to $1,738 million a year ago. Net income attributable to the company was $985 million or $1.15 per diluted share compared to $1,492 million or $1.75 per diluted share a year ago. Non-GAAP Net income attributable to the company was $2,395 million or $2.79 per diluted share compared to $2,120 million or $2.48 per diluted share a year ago. Net cash provided by operating activities was $2,834 million compared to $1,951 million a year ago. Non-GAAP operating income was $3,143 million compared to $2,768 million a year ago. For the second quarter ended June 30, 2015, the company reported impairment of long-lived assets of $81 million compared to $56 million a year ago. For the year 2015, the company raised EPS guidance, reflecting the positive momentum across the business. For the full year 2015, the company expects EPS to be in the range of $5.15 to $5.40 as compared to the previously provided EPS range of $5.05 to $5.35. The company expects net revenues of $19 billion - $19.4 billion, gross profit of 60.0% - 62.5%, operating income of $5.8 billion - $6 billion and cash flow from operations of $4.4 billion - $4.8 billion compared to previous guidance of net revenues of $19 billion - $19.4 billion, gross profit of 59.5% - 61.5%, operating income of $5.7 billion - $5.9 billion and cash flow from operations of $4.3 billion - $4.7 billion. The company expects to contribute approximately $2.7 billion in EBITDA in 2016. Excluding synergies, the company expects the combination to generate pro forma revenue of $26 billion and pro forma EBITDA of $9.5 billion in 2016 and strong cash flow from operations of approximately $7.5 billion in 2016 and expect increasing cash generation going forward.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVJF:US $69.24 USD 0.00

TEVJF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.69 USD -0.08
AbbVie Inc $70.01 USD -0.15
AstraZeneca PLC 4,320 GBp +0.50
Eli Lilly & Co $84.51 USD -0.03
Medtronic PLC $78.39 USD +0.11
View Industry Companies
 

Industry Analysis

TEVJF

Industry Average

Valuation TEVJF Industry Range
Price/Earnings 21.5x
Price/Sales 2.9x
Price/Book 2.6x
Price/Cash Flow 24.1x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL IND LTD, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.